Taking certain cholesterol drugs called evolocumab or alirocumab may help lower the chance of heart problems, whether you've already had heart issues or are just trying to prevent them.

From: Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.

Strongly supported

Multiple high-quality studies back this claim.

38
Pro
0
Against
quantitative
1 study

Not medical advice. For informational purposes only. Always consult a healthcare professional.

What this claim means

Taking certain cholesterol drugs called evolocumab or alirocumab may help lower the chance of heart problems, whether you've already had heart issues or are just trying to prevent them.

See the technical phrasing

The use of evolocumab or alirocumab is associated with a reduced risk of cardiovascular events in both primary and secondary prevention settings, with reported relative risks of 0.818 and 0.725 respectively, suggesting consistent benefit regardless of baseline cardiovascular disease status.

What the research says

Supports

1 study

38

Study: Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.

This study provides evidence supporting the claim.

Contradicts

0 studies

0

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.